This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development

JAMA. 1987;257(6):796-800.

Abstract
To examine the relationship between endometrial cancer and use of specific oral contraceptive (OC) formulations, we used data from the Cancer and Steroid Hormone Study, a multicenter, population-based, case-control study. Cases were 433 women aged 20 to 54 years with histologically confirmed epithelial endometrial cancer ascertained through six population-based cancer registries. Controls were 3191 women selected at random from the populations of these areas. Women who had used combination OCs for at least 12 months had an age-adjusted risk of developing endometrial cancer of 0.6 relative to those women who had never used OCs (95% confidence interval, 0.3 to 0.9). This protective effect persisted for at least 15 years after the cessation of OC use. Examination of the eight most frequently used OC formulations revealed little difference in the age-adjusted risks, which ranged from 0.2 to 0.7 for women who had ever used a formulation compared with women who had never used OCs. Use of OCs for 12 months or longer conferred protection against all three major histologic subtypes of endometrial cancer.

(JAMA 1987;257:796-800)

Author Affiliations
From the Division of Reproductive Health, Center for Health Promotion and Education, Centers for Disease Control, Atlanta.

Footnotes
Reprint requests to Epidemiological Studies Branch, Division of Reproductive Health, Center for Health Promotion and Education, Centers for Disease Control, Atlanta, GA 30333 (Nancy C. Lee, MD).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cancer Prevention: From 1727 to Milestones of the Past 100 Years
Lippman and Hawk
Cancer Res. 2009;69:5269-5284.
ABSTRACT | FULL TEXT  

Cancer Prevention Research: Back to the Future
Lippman
Cancer Prevention Research 2009;2:503-513.
FULL TEXT  

Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC)
Allen et al.
Endocr Relat Cancer 2008;15:485-497.
ABSTRACT | FULL TEXT  

Progestin Treatment Induces Apoptosis and Modulates Transforming Growth Factor-{beta} in the Uterine Endometrium
Rodriguez et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:578-584.
ABSTRACT | FULL TEXT  

Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review.
Lindor et al.
JAMA 2006;296:1507-1517.
ABSTRACT | FULL TEXT  

Combined oral contraceptives in the treatment of polycystic ovary syndrome
Vrbikova and Cibula
Hum Reprod Update 2005;11:277-291.
ABSTRACT | FULL TEXT  

Etiology of Hormone Receptor-Defined Breast Cancer: A Systematic Review of the Literature
Althuis et al.
Cancer Epidemiol. Biomarkers Prev. 2004;13:1558-1568.
ABSTRACT | FULL TEXT  

Good News about Oral Contraceptives
Davidson and Helzlsouer
NEJM 2002;346:2078-2079.
FULL TEXT  

Molecular Identification of Latent Precancers in Histologically Normal Endometrium
Mutter et al.
Cancer Res. 2001;61:4311-4314.
ABSTRACT | FULL TEXT  

Declining Cancer Rates in the 1990s
McKean-Cowdin et al.
JCO 2000;18:2258-2268.
ABSTRACT | FULL TEXT  

Hormonal carcinogenesis
Henderson and Feigelson
Carcinogenesis 2000;21:427-433.
ABSTRACT | FULL TEXT  

Contraception
Braverman and Strasburger
CLIN PEDIATR 1993;32:725-734.
ABSTRACT  

Hormonal Contraception
Baird and Glasier
NEJM 1993;328:1543-1549.
FULL TEXT